Chimeric antigen receptor (CAR)-T cell therapy has made impressive advancements in treating patients with blood cancers, such as leukemia and lymphoma, for more than a decade now. In this episode, we traverse the challenges and innovations of cell immunotherapy and better understand the design behind these logic-gated, genetically engineered cytotoxic cells with Dr. Yvonne Chen, a leading expert in the field. Dr. Chen is an incredibly accomplished Professor of the MIMG and CBE departments at UCLA and currently leads a Phase 1 Clinical Trial (NCT04007029) using bispecific anti-CD19/anti-CD20 CAR-T cells to treat patients with B cell malignancies. For more information on Dr. Chen’s research: http://yvchen.bol.ucla.edu/. Music: https://pixabay.com/music/id-112777/ Episode Team:Guests - Dr. Yvonne ChenHost - Brenda JiScript Writers - Brenda JiAudio - Daniel NguyenProducers - Artin Allahverdian, Sonali JoshiDirector - Vy Han, MD

Ver todos los episodios